Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Edgewise Therapeutics Inc.
Headquarters: Boulder, CO, United States of America
Website: http://www.edgewisetx.com
Year Founded: 2017
Status: Public
Industry Sector: HealthTechnology
CEO: Kevin Koch, PhD
Number Of Employees: 110
Enterprise Value: $2,002,037,514
PE Ratio: -7.96
Exchange/Ticker 1: NASDAQ:EWTX
Exchange/Ticker 2: N/A
Latest Market Cap: $1,095,812,992
BioCentury | Apr 4, 2025
Finance
Isomorphic’s $600M funding among four megarounds: Finance Report
Other nine-digit financings go to Airna, Atsena, Neurona
BioCentury | Jan 23, 2025
Management Tracks
New COOs for Vividion, Edgewise
Plus: Pacira names new heads of commercial, CBO and updates from Vib spinout Tanai, Arcus, Kyverna and Alx
BioCentury | Dec 18, 2024
Product Development
Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report
Plus: Readouts from Sanofi-Teva, Bicycle and more
BioCentury | Jan 26, 2024
Management Tracks
Karuna vet Paul among new Third Rock venture partners
Plus: three new executives at Soleno and updates from Zentalis, Slingshot, Actio, Kronos, Osivax, Cellular Origins and ConcertAI
BioCentury | Jan 19, 2024
Finance
Public equity roundup: Edgewise shares get lift after $240M offering
Plus offerings by Immatics, Viridion, Alector, LegoChem and more
BioCentury | Dec 20, 2022
Management Tracks
MorphoSys’ CFO Lee leaving
Plus: Mestag names Logtenberg as chair and updates from Edgewise, Myriad and Venatorx
BioCentury | Sep 21, 2022
Product Development
How venture philanthropy is driving modality innovation for DMD
Targeted antisense and non-viral gene therapies top CureDuchenne’s technology priority list
BioCentury | Jan 6, 2022
Finance
Jan. 5 Quick Takes: Eventide leads mega-round by Korro
Plus Saliogen raises $115M series B and updates from
BioCentury | Jun 5, 2021
Targets & Mechanisms
Going beyond genetic medicines for muscular dystrophy
Muscular dystrophy programs in the clinic cover not only a range of muscle mechanisms but also anti-fibrotic and anti-inflammation ones
BioCentury | Apr 29, 2021
Management Tracks
Cytovia names Frankel CMO; plus Bantam, GreenLight, Edgewise, CohBar and more
CAR NK cell therapy and antibody play Cytovia Therapeutics Inc. hired Stanley Frankel as CMO. Frankel was SVP of cellular therapy development at Bristol Myers Squibb Co. (NYSE:BMY). Bantam
Items per page:
1 - 10 of 12